New insight into epirubicin cardiac toxicity: Competing risks analysis of 1097 breast cancer patients

Journal of the National Cancer Institute

Volumn 100, Issue 15, 2008, Pages 1058-1067

  Ryberg, Marianne ^a   Nielsen, Dorte ^a   Cortese, Giuliana ^b   Nielsen, Gitte ^a   Skovsgaard, Torben ^a   Andersen, Per Kragh ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY OF PADOVA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; EPIRUBICIN; FLUOROURACIL; METHOTREXATE; TAMOXIFEN; VINDESINE;

ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ADULT; AGE; AGED; ARTICLE; BREAST CANCER; CANCER PATIENT; CANCER RADIOTHERAPY; CARDIOTOXICITY; CONGESTIVE HEART FAILURE; DEATH; DISEASE PREDISPOSITION; FEMALE; HUMAN; IRRADIATION; MAJOR CLINICAL STUDY; MEDIASTINUM; METASTASIS; MORTALITY; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RECOMMENDED DRUG DOSE; RISK ASSESSMENT; RISK FACTOR; STATISTICAL ANALYSIS; TUMOR VOLUME;

ADULT; AGE FACTORS; AGED; ANTHRACYCLINES; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CISPLATIN; CYCLOPHOSPHAMIDE; DENMARK; DISEASE SUSCEPTIBILITY; DRUG ADMINISTRATION SCHEDULE; EPIRUBICIN; FEMALE; FLUOROURACIL; HEART; HEART FAILURE; HUMANS; METHOTREXATE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROPORTIONAL HAZARDS MODELS; RADIOTHERAPY, ADJUVANT; RETROSPECTIVE STUDIES; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TAMOXIFEN; VINDESINE;

EID: 49449107089     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djn206     Document Type: Article

References (32)

1. Tormey DC. Adriamycin (NSC-123 127) in breast cancer: an overview of studies. Cancer Chemother Rep. 1975;6(2):319-327.
2. von Hoff D, Layard MW, Basa P, et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med. 1979;91(5):710-717.
3. Goldin A, Vendini JM, Geran R. The effectiveness of the anthracycline analogue 4′-epidoxorubicin in the treatment of experimental tumours: a review. Invest New Drugs. 1985;3(1):3-21.
4. Brambilla C, Rossi A, Bonefante V, et al. Phase II study of doxorubicin versus epirubicin in advanced breast cancer. Cancer Treat Rev. 1986;70(2):261-266.
5. Jain KK, Casper ES, Geller NL, et al. A prospective randomised comparison of epirubicin and doxorubicin in advanced breast cancer. J Clin Oncol. 1985;3(6):818-826.
6. Swain SM, Whaley SF, Ewer SM. Congestive heart failure in patients treated with doxorubicin. Cancer. 2003;97(11): 2869-2879.
7. Ryberg M, Nielsen D, Skovsgaard T, Hansen J, Jensen BV, Dombernowsky P. Epirubicin cardiotoxicity: an analysis of 469 patients with metastatic breast cancer. J Clin Oncol. 1998;16(11):3502-3508.
8. Andersen PK, Abildstrom SZ, Rosthoej S. Competing risks as a multistate model. Stat Methods Med Res. 2002;11(2):203-215.
9. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competitive risks: new representations of old estimates. Stat Med. 1999;8(6):695-706.
10. Criteria Committee of the New York Heart Association. Diseases of the Heart and the Great Vessels. Nomenclature and Criteria for Diagnosis. Boston, MA: Little Brown & Co; 1994. p. 253-256.
11. Nielsen D, Dombernowsky P, Skovsgaard T, Andersen JE, Engelholm SA, Hansen M. Epirubicin and epirubicin and vindesine in advanced breast cancer. A phase III study. Ann Oncol. 1996;1(4):275-280.
12. Nielsen D, Dombernowsky P, Larsen SK, Hansen OP, Skovsgaard T. Epirubicin or epirubicin and cisplatin as first-line therapy in advanced breast cancer. Cancer Chemother Pharmacol. 2000;46(6):439-466.
13. Nielsen D, Jensen JB, Dombernowsky P. Epirubicin cardiotocixity: a study of 135 patients with advanced breast cancer. J Clin Oncol. 1990;8(11):1806-1810.
14. Nazarewicz RR, Zenebe JW, Parihar A, Larson SK, Alidema EA, Ghafourifar P. Tamoxifen induces oxidative stress and mitochondrial apoptosis via stimulating mitochondrial nitric oxide synthase. Cancer Res. 2007;67(3):1282-1290.
15. Mandlekar S, Yu R, Tau TH, Kong ANT. Activation of caspase-3 and x-Jun NH2-terminal kinase-1 signalling pathways in tamoxifen-induced apoptosis of human breast cancer cells. Cancer Res. 2001;60(21):5995-6000.
16. Chang J, Xie M, Shah VR, et al. Activation of Rho-associated coiled-coil protein kinase 1 (ROCK-1) by caspase-3 cleavage plays an essential role in cardiac myocyte apoptosis. Proc Natl Acad Sci USA. 2006;103(39):14495- 14500.
17. The Breast International Group (BIG) 1-98 Collaborative group. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med. 2005;353(7):2747-2757.
18. de Jonge ME, Huitema ADR, Rodenhuis S, Beijnen JH. Clinical pharmacokinetics of cyclophosphamide. Clin Pharmacokinet. 2005;11(44):1135-1164.
19. Tsibiri P, Descortes J, Lombard-Bohas C, et al. Cardiotoxicity of 5-fluorouracil. Bull Cancer. 2006;3(93):27-30.
20. Doyle J, Neugut AI, Jacobson JS, Grann VR, Hershmann DL. Chemotherapy and cardiotoxicity in older breast cancer patients: a population-based study. J Clin Oncol. 2005;23(34):8597-8605.
21. Hooning MJ, Botma A, Aleman BMP, et al. Long-term risk of cardiovascular disease in 10-years survivors of breast cancer. J Natl Cancer Inst. 2007;99(5):365-375.
22. Mythili Y, Sudharsan PT, Varalakshmi P. Insights into the role of DL-alfa-lipoic acid against cyclophosphamide induced alterations in calcium sensitivity of cardiac myofilaments. Mol Cell Biochem. 2006;289(1-2):31-37.
23. Abraham P, Sugumar E. Increased glutathione levels and activity of PONI1 (phenyl acetate esterase) in the liver of rats after a single dose of cyclophosphamide: a defense mechanism? Exp Toxicol Pathol. 2007;59(5):301-306.
24. de Jonge ME, Huitema ADR, van Dam SM, Rodenhuis S, Beijnen JH. Population pharmacokinetics of cyclophosphamide and its metabolites 2- hydroxycyclophosphamide, 2-dechloroethylcyclophosphamide, and phosphamide mustard in high-dose combination with thiotepa and carboplatin. Ther Drug Monit. 2005;27(6): 756-764.
25. Li L, Pan Q, Han W, Liu Z, Li L, Hu X. Schisandrin B prevents doxorubicin-induced cardiotoxicity via enhancing gluthatione redox cycling. Clin Cancer Res. 2007;13(22): 6753-6760.
26. Hojris I, Overgaard M, Christensen JJ, Overgaard J. Morbidity and mortality of ischemic heart disease in high-risk breast-cancer patients after adjuvant post mastectomy systemic treatment with and without radiotherapy: analysis of DBCG 82b and 82c randomised trials. Lancet. 1991;354(9188):1425-1430.
27. Adams JM, Lipshultz SE, Schwarts C, et al. Radiation-associated cardiovascular disease: manifestations and management. Semin Oncol. 2003;13(3):346-356.
28. Lee CK, Aeppli D, Nierengarten ME. The need for long-term surveillance for patient treated with curative radiotherapy for Hodgkin's disease: University of Minnesota experience. Int J Radiat Oncol Biol Phys. 2000;48(1):169-179.
29. Falkson G, Gelman R, Falkson CI, Glick J, Harris J. Factors predicting for response, time to treatment failure, and survival in patients with metastastic breast cancer treated with DAVTH. J Clin Oncol. 1991;9(12):2153-2161.
30. Hotobagyi GN, Smith TL, Legha SS, Swenerton KD, Gehan EA, Yap HY et al. Multivariate analysis of prognostic factors in metastatic breast cancer. J Clin Oncol. 1983;1(12):776-786.
31. Ryberg M, Nielsen D, Osterlind K, Skovsgaard T, Dombernowsky P. Prognostic factors and long-term survival in 585 patients with metastatic breast cancer treated with epirubicin-based chemotherapy. Ann Oncol. 2001;12(1):81-87.
32. Jensen BV. Cardiotoxic consequences of anthracycline-containing therapy in patients with breast cancer. Semin Oncol. 2006;33 (3 Suppl 8):S15-21.